It was an honour to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) around his presentation, a sub analysis of the OPTIMUM study (ClinicalTrials.gov identifier: NCT02425644), entitled: P0071 – Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study.
Questions
1. Could you give us a brief overview of the OPTIMUM study and its major findings? (0:06)
2. What were the findings of your analysis of prespecified magnetic resonance imaging-based endpoints and no evidence of disease activity (NEDA) status? (2:58)
See also the 2nd part of this interview here.
Disclosures: Dr Kappos reports receiving grants from Actelion, Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, CSL Behring, Desitin, Eisai, Excemed, Genzyme, INNO Swiss, Japan Tabacco, Merck, Novartis, Roche, Pfizer, Receptos, Sanofi, Santhera and Teva; other from Neurostatus; and grants from the European Union, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
